In the latest trading session, 2.02 million Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares changed hands as the company’s beta touched 0.89. With the company’s most recent per share price at $5.26 changed hands at -$0.29 or -5.14% at last look, the market valuation stands at $1.60B. IOVA’s current price is a discount, trading about -248.48% off its 52-week high of $18.33. The share price had its 52-week low at $5.05, which suggests the last value was 3.99% up since then.
Analysts gave the Iovance Biotherapeutics Inc (IOVA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.40. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended IOVA as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Iovance Biotherapeutics Inc’s EPS for the current quarter is expected to be -0.27.
Iovance Biotherapeutics Inc (NASDAQ:IOVA) trade information
Instantly IOVA was in red as seen in intraday trades today. With action -5.31%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -28.85%, with the 5-day performance at -5.31% in the red. However, in the 30-day time frame, Iovance Biotherapeutics Inc (NASDAQ:IOVA) is -15.76% down.
The consensus price target for the stock as assigned by Wall Street analysts is 12.25, meaning bulls need an upside of 57.06% from its recent market value. According to analyst projections, IOVA’s forecast low is 7.5 with 17 as the target high. To hit the forecast high, the stock’s price needs a -223.19% plunge from its current level, while the stock would need to soar -42.59% for it to hit the projected low.
Iovance Biotherapeutics Inc (IOVA) estimates and forecasts
Year-over-year growth is forecast to reach 13,579.02% up from the last financial year.
Consensus estimates given by 13 financial analysts project the company’s revenue in the current quarter to hit an average of 72.17M. 9 analysts are of the opinion that Iovance Biotherapeutics Inc’s revenue for the current quarter will be 86.48M. The company’s revenue for the corresponding quarters a year ago was 482k and 715k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 14,873.88%. The estimates for the next quarter sales put growth at 11,995.74%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -8.25%. The 2025 estimates are for Iovance Biotherapeutics Inc earnings to increase by 31.49%, but the outlook for the next 5-year period is at 45.45% per year.
Iovance Biotherapeutics Inc (NASDAQ:IOVA)’s Major holders
PERCEPTIVE ADVISORS LLC holds the second largest percentage of outstanding shares, with 9.1052% or 25.93 million shares worth $207.98 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF. With 8.72 shares estimated at $45.86 million under it, the former controlled 2.86% of total outstanding shares. On the other hand, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF held about 2.34% of the shares, roughly 7.13 shares worth around $37.5 million.
